PORTFOLIO NEWS Surrozen Reports First Quarter 2022 Financial Results May 11, 2022 Read More » eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022 Read More » Nurix Therapeutics to Host R&D Day on May 26, 2022 May 9, 2022 Read More » ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update May 9, 2022 Read More » Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress May 9, 2022 Read More » NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results May 5, 2022 Read More » RAPT Therapeutics Expands Leadership Team with Multiple Key Hires May 4, 2022 Read More » Plexium Appoints Stephen Mullennix as Chief Financial Officer May 3, 2022 Read More » Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 2, 2022 Read More » Plexium and Abbvie Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions April 28, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update May 10, 2022 Read More »
ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update May 9, 2022 Read More »
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress May 9, 2022 Read More »
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results May 5, 2022 Read More »
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 2, 2022 Read More »
Plexium and Abbvie Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions April 28, 2022 Read More »
